Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CARsgen Therapeutics Holdings Limited
  6. Summary
    2171   KYG1996C1006

CARSGEN THERAPEUTICS HOLDINGS LIMITED

(2171)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/24/2021 11/25/2021 11/26/2021 11/29/2021 11/30/2021 Date
41 41.8 41.05 40.8 39.8 Last
569000 210000 158000 141500 514500 Volume
-3.76% +1.95% -1.79% -0.61% -2.45% Change
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 - - -
Net cash position 2021 2 570 M 404 M 404 M
P/E ratio 2021 -30,9x
Yield 2021 -
Sales 2022 - - -
Net income 2022 - - -
Net cash position 2022 1 639 M 258 M 258 M
P/E ratio 2022 -27,9x
Yield 2022 -
Capitalization 18 430 M 2 896 M 2 897 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 444
Free-Float 40,0%
More Financials
Company
CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which... 
More about the company
All news about CARSGEN THERAPEUTICS HOLDINGS LIMITED
11/22CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell ..
PR
11/22CARsgen Therapeutics Gets Greenlight to Start Immunotherapy's Clinical Trials in Canada
MT
11/22CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Au..
CI
11/15CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the E..
PR
11/15CARsgen Therapeutics Holdings Limited Announces Car T-Cell Product Candidate Ct041 Gran..
CI
11/15CARsgen's Cell Therapy Admitted to EU Priority Medicines Program; Shares Jump 6%
MT
10/04CARSGEN THERAPEUTICS : Wins Regulatory Nod to Start Phase Two Trial of Myeloma Treatment i..
MT
10/03CARsgen Therapeutics Holdings Limited Receives No-Objection Letter from Health Canada i..
CI
09/24CARsgen Therapeutics Holdings Limited Reports Unaudited Consolidated Earnings Results f..
CI
09/19CARSGEN THERAPEUTICS : Presents Cell Therapy Trial Data at Oncology Conference; Shares Fal..
MT
08/25CARSGEN THERAPEUTICS : Doses First Patient in Phase II Trial of Potential Multiple Myeloma..
MT
08/25Carsgen Therapeutics Holdings Limited Enrolls First Subject and Dosed in the Pivotal Ph..
CI
08/23Carsgen Therapeutics Holdings Limited Announces Unaudited Consolidated Earnings Results..
CI
08/23CARSGEN THERAPEUTICS : to be Added to Hang Seng Composite Index; Shares Rise 3%
MT
08/22CARSGEN THERAPEUTICS : Voluntary announcement - inclusion of carsgen as a constituent stoc..
PU
More news
News in other languages on CARSGEN THERAPEUTICS HOLDINGS LIMITED
11/22CARsgen Therapeutics obtient le feu vert pour commencer les essais cliniques de l'immun..
11/15La thérapie cellulaire de CARsgen admise au programme de médicaments prioritaires de l'..
10/04CARsgen Therapeutics obtient le feu vert des autorités réglementaires pour lancer un es..
09/19CARsgen Therapeutics présente les résultats d'un essai de thérapie cellulaire à une con..
More news
Chart CARSGEN THERAPEUTICS HOLDINGS LIMITED
Duration : Period :
CARsgen Therapeutics Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARSGEN THERAPEUTICS HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 32,48 CNY
Average target price 44,52 CNY
Spread / Average Target 37,0%
EPS Revisions
Managers and Directors
Zong Hai Li Chairman, Chief Executive & Scientific Officer
Hua Mao Wang Chief Operating Officer & Executive Director
Chun Hai Fan Independent Non-Executive Director
Yi Fan Li Independent Non-Executive Director
Guang Mei Yan Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CARSGEN THERAPEUTICS HOLDINGS LIMITED0.00%2 968
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.28.27%66 062
VERTEX PHARMACEUTICALS-19.56%48 336